Claudia Albertini

Dr. Claudia Albertini

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2019 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
VIViktoriya Ivasiv
Viktoriya Ivasiv
CAClaudia Albertini
Claudia Albertini
AGAna Elisa Goncalves
Ana Elisa Goncalves
MRMichele Rossi
Michele Rossi
MBMaria Laura Bolognesi
Maria Laura Bolognesi
Molecular hybridization is a well-exploited medicinal chemistry strategy that aims to combine two molecules (or parts of them) in a new, single chemical entity. Recently, it has been recognized as an effective approach to design ligands able to modulate multiple targets of interest. Hybrid compounds can be obtained by linking (presence of a linker) or framework integration (merging or fusing) strategies. Although very promising to combat the multifactorial nature of complex diseases, the development of molecular hybrids faces the critical issues of selecting the right target combination and the achievement of a balanced activity towards them, while maintaining drug-like-properties. In this review, we present recent case histories from our own research group that demonstrate why and how molecular hybridization can be carried out to address the challenges of multitarget drug discovery in two therapeutic areas that are Alzheimer’s and parasitic diseases. Selected examples spanning from linker- to fragment- based hybrids will allow to discuss issues and consequences relevant to drug design.

19 June 2020 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
CAClaudia Albertini
Claudia Albertini
ASAlessandra Salerno
Alessandra Salerno
PPPedro de Sena Murteira Pinheiro
Pedro de Sena Murteira Pinheiro
MBMaria Laura Bolognesi
Maria Laura Bolognesi

27 July 2020 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
RPRosaria Perone
Rosaria Perone
CAClaudia Albertini
Claudia Albertini
EUElisa Uliassi
Elisa Uliassi
FPFlaminia Di Pietri
Flaminia Di Pietri
PPPedro de Sena Murteira Pinheiro
Pedro de Sena Murteira Pinheiro
MBMaria Laura Bolognesi
Maria Laura Bolognesi

19 February 2021 in Molecules
Verified
Journal Article
Open access
PDF file
CAClaudia Albertini
Claudia Albertini
MNMarina Naldi
Marina Naldi
SPSabrina Petralla
Sabrina Petralla
SSSilvia Strocchi
Silvia Strocchi
Daniela GrifoniDaniela Grifoni
Daniela Grifoni
MBMaria Laura Bolognesi
Maria Laura Bolognesi
Despite Alzheimer’s disease (AD) incidence being projected to increase worldwide, the drugs currently on the market can only mitigate symptoms. Considering the failures of the classical paradigm “one target-one drug-one disease” in delivering effective medications for AD, polypharmacology appears to be a most viable therapeutic strategy. Polypharmacology can involve combinations of multiple drugs and/or single chemical entities modulating multiple targets. Taking inspiration from an ongoing clinical trial, this work aims to convert a promising cromolyn–ibuprofen drug combination into single-molecule “codrugs.” Such codrugs should be able to similarly modulate neuroinflammatory and amyloid pathways, while showing peculiar pros and cons. By exploiting a linking strategy, we designed and synthesized a small set of cromolyn–ibuprofen conjugates (4–6). Preliminary plasma stability and neurotoxicity assays allowed us to select diamide 5 and ethanolamide 6 as promising compounds for further studies. We investigated their immunomodulatory profile in immortalized microglia cells, in vitro anti-aggregating activity towards Aβ42-amyloid self-aggregation, and their cellular neuroprotective effect against Aβ42-induced neurotoxicity. The fact that 6 effectively reduced Aβ-induced neuronal death, prompted its investigation into an in vivo model. Notably, 6 was demonstrated to significantly increase the longevity of Aβ42-expressing Drosophila and to improve fly locomotor performance.

19 June 2026 in ChemRxiv
Verified
Preprint
Open access
XLXiaojun Julia Liang
Xiaojun Julia Liang
CAClaudia Albertini
Claudia Albertini
TKThales Kronenberger
Thales Kronenberger
ESEkaterina Shevchenko
Ekaterina Shevchenko
ARAlexander Rasch
Alexander Rasch
Matthias GehringerMatthias Gehringer
Matthias Gehringer
The tyrosine kinase expressed in hepatocellular carcinoma (TEC) family comprises five non-receptor tyrosine kinases – BTK, ITK, BMX, TXK, and TEC – with key roles in immune signalling. Although BTK and ITK have been extensively studied, selective inhibitors for TEC, TXK, and BMX remain scarce. Recently, we identified 7-azaindole-based covalent BMX inhibitors with potent inhibitory activity and robust cellular target engagement but limited selectivity across TEC family members, especially BTK. Here, we describe a new generation of BMX inhibitors designed to exploit subtle structural differences between BMX and BTK by incorporating diverse N-acylamino substituents at the azaindole 5-position or variations at the linker and warhead. Our compounds display subnanomolar BMX potency and improved selectivity over BTK and other TEC kinases. Key compound 11i showed strong cellular target engagement, good in vitro metabolic stability, a favourable kinome profile, and rapid covalent inactivation kinetics, positioning it among the best BMX chemical probes currently available.

30 April 2026 in ChemRxiv
Verified
Preprint
Open access
XLXiaojun Julia Liang
Xiaojun Julia Liang
CAClaudia Albertini
Claudia Albertini
TKThales Kronenberger
Thales Kronenberger
ESEkaterina Shevchenko
Ekaterina Shevchenko
ARAlexander Rasch
Alexander Rasch
Matthias GehringerMatthias Gehringer
Matthias Gehringer
The Tyrosine Kinase Expressed in Hepatocellular Carcinoma (TEC) family comprises five nonreceptor tyrosine kinases – BTK, ITK, BMX, TXK, and TEC – which play key roles in immunological signal transduction. Although BTK and ITK have been extensively studied, selective inhibitor development for TEC, TXK, and BMX remains scarce. In a recent study, we identified a new class of covalent BMX inhibitors with a 7-azaindole core. These compounds exhibit potent inhibitory activity and robust cellular target engagement but had limited selectivity across TEC family members, especially BTK, which is the closest relative of BMX. Here, we describe the next generation of BMX inhibitors that incorporate diverse N-acylamino substituents at the azaindole 5-position or variations in the linker and warhead region. These modifications were designed to exploit subtle structural differences between BMX and BTK in the pocket behind the gatekeeper residue as well as in the front pocket. Our compounds display excellent BMX potency in the sub-nanomolar range along with improved selectivity against BTK and other TEC family kinases. We identified compound 11i as a new BMX lead compound with strong cellular target engagement, good in vitro metabolic stability, a favourable kinome profile, and fast covalent inactivation kinetics. These properties position compound 11i among the best BMX chemical probes currently available.